25
https://pubmed.ncbi.nlm.nih.gov/38112286
A peptide immunotherapy for peanut allergy, PVX108, is found to be safe and shows potential for durable allergen-specific immune modulation in a Phase 1 trial.
https://pubmed.ncbi.nlm.nih.gov/38112286
A peptide immunotherapy for peanut allergy, PVX108, is found to be safe and shows potential for durable allergen-specific immune modulation in a Phase 1 trial.